What are the key structural features of oral PROTACs?

Oral PROTACs typically have a molecular weight under 1000 Da, a limited number of rotatable bonds (often fewer than 15), and a moderate lipophilicity (clogP between 2 and 5). They also incorporate a stable linker connecting the target-binding and E3 ligase-binding moieties to enhance oral bioavailability.

How do physicochemical properties affect the oral bioavailability of PROTACs?

Physicochemical properties like solubility, permeability, and metabolic stability directly influence oral absorption and systemic exposure. For PROTACs, balancing aqueous solubility with membrane permeability is critical, often achieved by optimizing hydrogen bond donors and acceptors.

What is the typical molecular weight range for orally bioavailable PROTACs?

Orally bioavailable PROTACs generally have a molecular weight below 1000 Da, with many successful examples in the 700–900 Da range. Higher molecular weights tend to reduce permeability and increase efflux by transporters like P-glycoprotein.

Why is linker design important for oral PROTACs?

The linker length, composition, and flexibility affect the ternary complex formation and overall physicochemical properties. A well-designed linker can improve solubility and reduce aggregation, while also preventing premature metabolism and enhancing oral exposure.

Structural and Physicochemical Features of Oral PROTACs

Oral PROTACs (proteolysis-targeting chimeras) represent a shift in drug design, but their oral bioavailability remains the central challenge. The structural and physicochemical features that determine success hinge on a narrow set of molecular properties: a molecular weight typically below 1000 Da, a logP between 2 and 5, fewer than 3 hydrogen bond donors, and a polar surface area under 140 Å². These parameters directly influence permeability, solubility, and metabolic stability, and they are far stricter than those for injectable PROTACs.

The Molecular Weight Barrier

The most immediate obstacle for oral PROTACs is their size. A typical PROTAC consists of a target-binding ligand, an E3 ligase ligand, and a linker, which together often push molecular weight above 1000 Da. Oral drugs generally require a molecular weight below 500 Da for reliable absorption, but PROTACs can sometimes succeed up to about 1000 Da if other properties are optimized.

For example, a PROTAC with a molecular weight of 950 Da might still achieve oral absorption if it has a very low hydrogen bond donor count (ideally 0 or 1) and a logP near 3.5. The linker is the main contributor to size, so shortening it or using rigid, low-molecular-weight linkers (such as triazoles or small alkyl chains) is a common strategy. The key is that every atom added to the linker must be justified by improved target engagement or metabolic stability, not just convenience.

Hydrogen Bond Donors and Permeability

Hydrogen bond donors (HBDs) are a critical filter. Oral PROTACs typically need 2 or fewer HBDs to cross the intestinal epithelium. Each additional donor reduces passive permeability and increases the likelihood of efflux by P-glycoprotein.

The E3 ligase ligands often introduce HBDs. For instance, the widely used von Hippel-Lindau (VHL) ligand contains a hydroxyl group that acts as a donor. To compensate, medicinal chemists frequently mask this group with a prodrug strategy or replace it with a methyl ether. Alternatively, using cereblon-based ligands, which have fewer HBDs, can simplify the design. A practical rule is that any PROTAC with more than 3 HBDs is unlikely to achieve oral bioavailability above 10% in preclinical models.

LogP and Lipophilicity Balance

LogP, a measure of lipophilicity, must be kept between 2 and 5 for oral PROTACs. Below 2, the compound struggles to cross lipid membranes; above 5, it becomes too insoluble and prone to metabolic clearance.

The linker is the easiest place to adjust logP. Polyethylene glycol (PEG) linkers increase hydrophilicity (lower logP), while alkyl chains increase lipophilicity (higher logP). A common approach is to use a short PEG linker (2-4 units) to keep logP near 3.5. However, PEG linkers also increase molecular weight and can reduce metabolic stability. An alternative is to use rigid linkers like piperazine or piperidine, which contribute less to logP while improving conformational control.

Polar Surface Area and Solubility

Polar surface area (PSA) is a direct predictor of passive permeability. Oral PROTACs typically need a PSA below 140 Å², and ideally below 120 Å², to achieve sufficient absorption. The E3 ligase ligand and the target ligand both contribute polar groups, so the linker must be designed to minimize additional polarity.

Solubility is the other side of this equation. A PROTAC with low PSA (good permeability) may still fail if it is too insoluble to dissolve in the gastrointestinal tract. The target is a kinetic solubility of at least 50 µM at pH 6.8. Adding a single ionizable group, such as a basic amine in the linker, can improve solubility without drastically increasing PSA. For example, a piperazine ring in the linker can provide a pKa around 8-9, allowing the compound to protonate in the stomach and dissolve, then deprotonate in the intestine for absorption.

Metabolic Stability and First-Pass Clearance

Oral PROTACs must survive first-pass metabolism in the liver and gut wall. The linker is often the site of metabolic cleavage, especially if it contains esters or amides. Replacing a labile ester with a stable amide or a triazole can improve half-life.

The E3 ligase ligand also affects metabolism. VHL ligands contain a hydroxyproline motif that is susceptible to glucuronidation. Using a cereblon ligand or modifying the VHL scaffold to block the hydroxyl group can reduce clearance. In practice, a PROTAC with a human liver microsome half-life below 30 minutes is unlikely to achieve oral exposure sufficient for once-daily dosing.

A Worked Example: ARV-110

ARV-110 (bavdegalutamide) is an oral PROTAC targeting the androgen receptor for prostate cancer. It uses a cereblon E3 ligase ligand, which keeps HBDs low (2 donors), and a short alkyl linker. Its molecular weight is around 850 Da, logP near 4, and PSA around 120 Å². These values fall within the acceptable range for oral PROTACs, and clinical trials have shown measurable oral bioavailability in patients.

This example illustrates the trade-offs: the cereblon ligand avoids the HBD problem of VHL, but the alkyl linker increases logP, requiring careful formulation. ARV-110 is dosed as a capsule, and its oral bioavailability is estimated at 10-20% in humans, which is sufficient for efficacy.

The Role of the Linker in Conformational Control

The linker is not just a passive connector; it determines how the two ligands orient in space. For oral PROTACs, the linker must allow the formation of a stable ternary complex between the target protein, the PROTAC, and the E3 ligase. A rigid linker, such as a short alkynyl or triazole chain, can pre-organize the molecule into a bioactive conformation, reducing the entropic penalty of binding. This rigidity also helps limit molecular flexibility, which improves permeability by reducing the number of rotatable bonds.

A practical example is the use of a piperidine ring as a linker core. Piperidine provides a single rotatable bond at each attachment point, keeping the total rotatable bond count below 10. PROTACs with more than 10 rotatable bonds typically show poor oral absorption because they adopt too many conformations in solution, many of which are not membrane-permeable. The linker should also avoid amide bonds that can act as hydrogen bond donors; replacing an amide with a sulfonamide or a simple ether linkage can reduce HBD count while maintaining stability.

Permeability and Efflux Transporters

Passive permeability is not the only barrier; many PROTACs are substrates for efflux transporters, particularly P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). These transporters actively pump PROTACs back into the gut lumen, reducing net absorption.

The likelihood of efflux increases with molecular weight and the presence of aromatic rings. PROTACs with more than 4 aromatic rings are almost always P-gp substrates. To reduce efflux, the linker can be designed to minimize aromatic content. For example, replacing a phenyl ring in the linker with a cyclohexane or a piperidine ring can reduce P-gp recognition while maintaining conformational rigidity.

In vitro assays using Caco-2 cells can measure efflux ratios. An efflux ratio above 2.5 indicates significant transporter involvement. For oral PROTACs, an efflux ratio below 2 is desirable. If efflux cannot be avoided, co-administration with a P-gp inhibitor, such as verapamil or cyclosporine, can improve absorption, but this is rarely practical for chronic dosing. A better approach is to modify the PROTAC structure to reduce its affinity for the transporter, often by reducing the number of hydrogen bond acceptors.

Key Takeaways

Oral PROTACs require molecular weight below 1000 Da, preferably under 900 Da, to have a realistic chance of oral absorption.
Hydrogen bond donors must be kept at 2 or fewer; using cereblon-based ligands helps meet this limit.
LogP should stay between 2 and 5, with 3-4 as the sweet spot for balancing permeability and solubility.
Polar surface area under 140 Å² is necessary for passive permeability; linkers should not add unnecessary polarity.
Metabolic stability depends on linker choice; avoid esters and labile amides, and consider the E3 ligase ligand’s metabolic liabilities.
A single ionizable group in the linker can improve solubility without harming permeability.
The linker must balance rigidity and flexibility; rigid linkers with fewer than 10 rotatable bonds improve permeability and ternary complex formation.
Efflux by P-gp is a major barrier; reducing aromatic ring count in the linker can lower efflux ratios.
Each structural modification involves trade-offs between permeability, solubility, stability, and potency; cellular assays are essential to validate the net benefit.
Consult a healthcare professional for medical advice regarding any specific PROTAC therapy.

Structural and Physicochemical Features of Oral PROTACs: A 2025 Guide